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Summary Background Trabectedin is a novel anticancer
agent used to treat soft tissue sarcoma (STS). This phase I
study of trabectedin was performed to determine the recom-
mended dose for phase II studies in Japanese patients with
STS. Methods Patients who had STS refractory to, or who
could not tolerate, anthracycline-based chemotherapy were
enrolled. The starting dose of trabectedin was 0.9 mg/m2,
given as a 24-h continuous infusion every 21 days. The dose
was escalated to 1.2 mg/m2 and then to 1.5 mg/m2, using a
“3+3” cohort expansion design. Plasma samples were collect-
ed for pharmacokinetic analysis. Results Fifteen patients re-
ceived 1 of 3 dose levels of trabectedin. Dose-limiting toxicity
occurred in two of three patients at 1.5 mg/m2: 1 had a grade 3
increase in creatine phosphokinase and grade 3 anorexia, and
the other had grade 4 platelet count decreased. Frequent grade
3 or 4 adverse events (AEs) included elevations of alanine
aminotransferase and aspartate aminotransferase and decrease
in neutrophil count. The frequency and severity of AEs were
clearly greater at 1.5 mg/m2 than at the lower doses.
Pharmacokinetic analysis showed that the area under the
concentration-time curve at a dose of 1.2 mg/m2 was adequate
to produce antitumor activity. A partial response was obtained
in three patients with translocation-related sarcomas (1 each
withmyxoid liposarcoma, synovial sarcoma, and extraskeletal
Ewing sarcoma). Conclusions The recommended dose of
trabectedin for phase II studies is 1.2 mg/m2 in Japanese
patients with STS. Trabectedin may be especially effective
against translocation-related sarcomas.
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Introduction
Soft tissue sarcomas (STS) are a heterogeneous group of rare
malignant tumors of mesenchymal origin that account for less
than 1 % of all adult malignancies. Chromosomal transloca-
tions are the most frequent molecular alterations in sarcomas,
occurring in about 20 % of cases [1]. Sarcoma translocations
and the associated chimeric oncoproteins provide attractive
targets for therapeutic intervention, given that these fusion
proteins are critical for disease pathogenesis and tumor-cell
survival, and no alternative pathways exist to avoid their
blockade [2–5].
Current treatment options for patients with STS vary ac-
cording to clinical stage, but include surgery, radiotherapy,
and chemotherapy [6]. As for chemotherapy, doxorubicin and
ifosfamide, given sequentially as single agents or in combina-
tion, have been used as standard treatment for most histologic
subtypes of advanced STS to date [7], however, the outcomes
of patients with advanced or metastatic sarcoma remain poor
over the past two decades, with an estimated median survival
of approximately 1 year from the start of first-line therapy
[8–11]. Recently, pazopanib, a multitargeted tyrosine kinase
inhibitor has demonstrated single-agent activity in patients
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with advanced STS subtypes, excluding liposarcomas, in a
phase III trial [12]. Several guidelines have included
pazopanib and other chemotherapy as options for palliative
therapy [13, 14], but there is a paucity of high-level evidence
to support.
Trabectedin is a tris tetrahydroisoquinoline alkaloid initial-
ly isolated from the marine ascidian, Ecteinascidia turbinata,
and is now produced synthetically. This agent binds to the
minor groove of DNA and interacts with proteins of the DNA
repair machinery, disrupting the cell cycle and inhibiting cell
proliferation [15]. Trabectedin has been approved in the
European Union and other countries worldwide, with the
exception of the United States and Japan, for the treatment
of advanced STS after failure of anthracycline and ifosfamide.
Some clinical guidelines recommend trabectedin as a second-
line option [13, 16, 17].
Pharmacokinetic studies of trabectedin administered as
24-h continuous infusion in patients with solid tumor showed
linearity within the dose range studied (0.05–1.8 mg/m2), with
large inter-patient variability and moderate intra-patient vari-
ability [18]. A population pharmacokinetic (PopPK) analysis
[19] derived from 603 cancer patients who received single-
agent trabectedin concluded that none of the subject covariates
were significantly related to between- or within-subject vari-
ability in the plasma clearance of trabectedin. Although
trabectedin is considered to have a narrow therapeutic index,
evidence suggesting ethnic differences in the safety and toler-
ability of trabectedin remains scant. Moreover, clinical trials
of trabectedin have been conducted mainly in the Caucasian
patients and there is little data of trabectedin for Asian
patients.
This was a phase I pharmacokinetic study of trabectedin in
Japanese patients with advanced STS. The primary objective
was to determine the recommended dose of trabectedin for
phase II studies in Japan.
Patients and methods
Patient eligibility
Patients were eligible if they were 18 years or older with an
Eastern Cooperative Oncology Group (ECOG) performance
status (PS) of 0 or 1, and had a histologically confirmed
diagnosis of STS and had received at least one
anthracycline-based regimen and a maximum of up to four
previous lines of systemic therapy for advanced disease.
Hematologic, hepatic and renal function had to be confirmed
based on laboratory assessment.
Patients were excluded if they had received surgery during
the 4 weeks before study entry; radiotherapy or chemotherapy
during the 3 weeks before study entry. Pregnant or breast-
feeding women were also ineligible, as were patients who had
any of the following conditions: severe complications;
symptomatic brain metastasis; a history of neoplasms;
pleural effusion, ascites, or pericardial fluid requiring
drainage.
The study was conducted in accordance with the
International Conference of Harmonization guideline for
Good Clinical Practice and with the Declaration of Helsinki.
The protocol was approved by an independent review board at
each investigational site, and written informed consent was
obtained from all patients before enrollment.
Treatment plan
Trabectedin was supplied by Taiho Pharmaceutical Co., Ltd.
(Tokyo, Japan) as a lyophilized powder in glass vials. The
drug was administered as a 24-h continuous intravenous infu-
sion via a central venous access catheter. Cycles were repeated
every 3 weeks until disease progression, unacceptable toxic-
ity, or withdrawal of consent. The starting dose was 0.9 mg/
m2, which is equivalent to half of the maximum tolerated dose
(MTD; 1.8 mg/m2) in a previous phase I study of solid tumors
[18] conducted in France. The maximum dose level was
1.5 mg/m2, which is the approved dose in the European
Union; a 1.2 mg/m2 dose was also evaluated as the midway
point between 0.9 and 1.5 mg/m2. Dose escalation followed a
3+3 design [20]. The MTDwas defined as the minimum dose
at which more than 33 % patients had dose-limiting toxicity
(DLT). The recommended dose for phase II clinical trials was
defined as the dose level below the MTD.
Assessments
Data on demographic characteristics and medical history were
collected during screening. Physical examination and vital
sign and safety assessments (PS, 12-lead electrocardiography,
and laboratory test) were conducted at baseline/screening and
throughout treatment.
Safety
Adverse events (AEs) were graded according to the National
Cancer Institute Common Toxicity Criteria (version 4.0). DLT
was defined as any of the following: grade 3 decrease in
platelet count requiring platelet transfusion; grade 4 decrease
in platelet count; grade 4 decrease in neutrophil count lasting
more than 5 days; febrile neutropenia; elevations of alanine
aminotransferase (ALT) or aspartate aminotransferase (AST)
to more than 5 times the upper limit of normal that do not
recover to 2.5 times the upper limit of normal by day 28; any
nonhematologic toxicity of grade ≥3.
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Tumor response
Tumor response was assessed according to the Response
Evaluation Criteria in Solid Tumors guidelines (version 1.1)
by the investigators at screening, every 6 weeks until week 24,
and every 9 weeks thereafter.
Pharmacokinetic studies
All patients underwent plasma pharmacokinetic studies be-
tween day 1 and day 8 of the first cycle. Heparinized whole
blood samples were collected before the start of infusion; 0.5
and 1.5 h after the start of infusion; immediately before the
end of infusion; and 0.5, 1, 2, 5, 8, 24, 48, 72, and 144 h after
the end of infusion. Plasma concentrations were measured
using a miniaturized liquid chromatography/tandem mass
spectrometry method as described elsewhere [21].
Pharmacokinetic variables were calculated by non-
compartmental analysis methods. Cmax was obtained
directly from pharmacokinetic data. The AUC up to
the last observed time (AUC0-t) was calculated with
the trapezoidal rule. The AUC0-inf was calculated as
the sum of AUC0-t and the extrapolated AUC, calculat-
ed from the terminal rate constant λz (Clast/λz, where
Clast is the last measured concentration). The elimination
half-life (tl/2) was calculated as 0.693/λz, and the total
plasma clearance (CL) was calculated as the dose divid-
ed by the AUC0-inf. The volume of distribution at steady state
(Vdss) was calculated by the formula CL×AUMC0-inf/AUC0-
inf, in which AUMC0-inf is the area under the first-order
moment curve.
Statistical analyses
Sample size was determined empirically, based upon a 3+3
escalation design. Descriptive statistics were used for analyses
of safety, tumor response, and pharmacokinetic variables.
Safety was analyzed on the basis of data for the first 4 cycles.
The data cutoff point for efficacy analysis was the end of July
2013.
Results
Patient characteristics and doses administered
Between September 2010 and September 2011, a total
of 15 patients received 1 of the 3 dose levels. Patient
characteristics are shown according to dose level in
Table 1. As for histological type of sarcoma, fusion
gene was confirmed in five patients (three patients with
synovial sarcoma and 1 each with extraskeletal Ewing
sarcoma and myxoid liposarcoma),
The median number of treatment cycles was 4, 4, and 2 at
dose level 1, 2, and 3, respectively.
Dose-limiting toxicity
DLT occurred in two patients at dose level 3. One patient had
creatine phosphokinase (CPK) increased (grade 3) and an-
orexia (grade 3), and the other had platelet count decreased
(grade 4). Both of these patients also had severe elevations of
ALT and AST (>2,000 IU/L) with no clinically significant
abnormalities of bilirubin or alkaline phosphatase and no sign
of hepatic impairment. These events resolved 7 to 12 days
after onset and did not meet the criteria for DLT.
Toxicity
The incidence rates of adverse drug reactions occurring in
three or more patients are shown according to dose level and
grade in Table 2. The incidence rate and severity of AEs
related to hepatic and bone-marrow toxicity increased in a
dose-related fashion. At dose level 2, a patient had a grade 4
increase in CPK, but recovered from the event after delaying
initiation of the next cycle. At dose level 3, all three patients
had severe increases in CPK, and rhabdomyolysis was diag-
nosed in 1 of these patients.
A total 13 serious AEs occurred in six patients (1 of 3
patients at dose level 1, 2 of 9 at dose level 2, and 3 of 3 at dose
level 3). Platelet count decreased and anorexia developed in
two or more patients. All serious AEs were attributed to
trabectedin and resolved after appropriate treatment. There
was no treatment-related death during the study. One patient
at dose level 2 and 2 patients at dose level 3 withdrew from the
study because of AEs related to trabectedin (neutrophil count
decreased, rhabdomyolysis, and platelet count decreased,
respectively).
Pharmacokinetics
Individual plasma concentrations of trabectedin are shown
in Fig. 1, and pharmacokinetic variables are shown in
Table 3. Plasma trabectedin concentrations decreased im-
mediately after the end of infusion, and the drug was
gradually eliminated. Mean AUCs increased in a dose-
dependent manner. In one patient given dose level 2, the
plasma trabectedin concentration abnormally rose again up
to 9,900 pg/mL 1 h after the completion of infusion.
Elimination at dose level 3 was slower than that at the
lower dose levels.
Patient responses
The maximum number of administered treatment cycles was
7, 19, and 2 at dose level 1, 2 and 3, respectively. In the 15
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patients, the response rate was 20 % (3 of 15) and the
progression-free rate (PFR) at 3 months was 60 % (9 of 15).
All three patients with partial response (PR) were at dose level
2 and had translocation-related sarcomas (TRS; myxoid
liposarcoma, synovial sarcoma, extraskeletal Ewing sarcoma
in one patient each) with confirmation of fusion genes (EWS-
CHOP1, SYT-SSX1, and EWS mutation, respectively).
The case of a patient who continues the longest treatment
with trabectedin is presented. A 13-year-old girl was given a
diagnosis of a retroperitoneal myxoid liposarcoma in 2004.
She received three lines of chemotherapy, including
pirarubicin, ifosfamide, and dacarbazine, and then underwent
surgery to remove the entire tumor from the pelvis. She had
relapse 2 years later, underwent surgery six times, and
Table 1 Patient characteristics
Level 1 (N=3) Level 2 (N=9) Level 3 (N=3) Total (N=15)
n (%) n (%) n (%) n (%)
Gender Male 1 (33.3) 5 (55.6) 2 (66.7) 8 (53.3)
Female 2 (66.7) 4 (44.4) 1 (33.3) 7 (46.7)








































PS 0 3 (100.0) 9 (100.0) 2 (66.7) 14 (93.3)
1 0 (0.0) 0 (0.0) 1 (33.3) 1 (6.7)
Histological type Leiomyosarcoma 2 (66.7) 2 (22.2) 1 (33.3) 5 (33.3)
Synovial sarocma 0 (0.0) 2 (22.2) 1 (33.3) 3 (20.0)
Extraskeletal Ewing tumor 0 (0.0) 1 (11.1) 0 (0.0) 1 (6.7)
Dediffrenciated liposarcoma 0 (0.0) 2 (22.2) 0 (0.0) 2 (13.3)
Myxoid liposarcoma 0 (0.0) 1 (11.1) 0 (0.0) 1 (6.7)
Solitary fibrous tumor 1 (33.3) 0 (0.0) 0 (0.0) 1 (6.7)
Spindle cell sarcoma 0 (0.0) 0 (0.0) 1 (33.3) 1 (6.7)
Alvolar soft part sarcoma 0 (0.0) 1 (11.1) 0 (0.0) 1 (6.7)
Primary Lesion Upper extremity 0 (0.0) 1 (11.1) 0 (0.0) 1 (6.7)
Lower extremity 0 (0.0) 1 (11.1) 1 (33.3) 2 (13.3)
Face 1 (33.3) 0 (0.0) 0 (0.0) 1 (6.7)
Intrathoracic 0 (0.0) 1 (11.1) 0 (0.0) 1 (6.7)
Chest, other 0 (0.0) 1 (11.1) 0 (0.0) 1 (6.7)
Retroperitoneal 0 (0.0) 4 (44.4) 0 (0.0) 4 (26.7)
Uterus 2 (66.7) 0 (0.0) 1 (33.3) 3 (20.0)
Abdomen/pelvis, other 0 (0.0) 1 (11.1) 1 (33.3) 2 (13.3)
Location of lesions at baselinea Lung 1 (33.3) 3 (33.3) 0 (0.0) 4 (26.7)
Liver 0 (0.0) 2 (22.2) 0 (0.0) 2 (13.3)
Lymph node 0 (0.0) 0 (0.0) 1 (33.3) 1 (6.7)
Soft tisuue 1 (33.3) 3 (33.3) 0 (0.0) 4 (26.7)
Other 1 (33.3) 3 (33.3) 1 (33.3) 5 (33.3)
Number of prior lines for advanced therapy Median 2.0 2.0 2.0 2.0
Range [Min, Max] [2, 3] [1, 10] [1, 4] [1, 10]
Analysis Set: FAS
SD standard deviation, PS performance status
aMultiple answers allowed
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received topotecan and vaccine therapy for advanced disease
over the course of 5 years. When she was 21 years of age, she
presented at a site participating in this study. The patient started
to receive trabectedin at dose level 2 in September 2011.
Magnetic resonance imaging (MRI) showed a retroperitoneal
lesion (longest diameter, 249 mm; Fig. 2a) at baseline. MRI
showed a 33 % reduction in tumor diameter (167 mm, Fig. 2b)
at 7 cycles and the shortest diameter was 83 mm at 13 cycles
(Fig. 2c). The latest diameter was 122 mm at 19 cycles
(Fig. 2d), which meet the criteria of progressive disease (PD.
Discussion
This phase I study of trabectedin in Japanese patients with
advanced STS indicated that the MTD is 1.5 mg/m2 and that
the recommended dose for phase II clinical trials is 1.2 mg/m2
in Japan.
Trabectedin 1.5 mg/m2 as 24-h infusion every 3 weeks
is approved by the European Medicines Agency (EMA) for
STS based on the results of a phase I study in patients with
solid tumors [18] and a phase II study in patients with
liposarcoma or leiomyosarcoma, which showed that
trabectedin 1.5 mg/m2 every 3 weeks was associated with
a longer time to progression than 0.58 mg/m2 every week
[22].
In our study, two of three patients at dose level 3 had DLT,
and the third patient had rhabdomyolysis and withdrew. All
three patients also had serious AEs at dose level 3. At dose
level 2, no patient had DLT. Only one patient withdrew from
the study because of trabectedin-related neutrophil count
decreased.
The incidence of adverse drug reactions increased in par-
allel to the dose of trabectedin. The number of grade 3 and 4
events including increase in hepatic transaminase and CPK
was higher at dose level 3 than at dose level 1 or 2. Based on
our safety data, we estimated that 1.2 mg/m2 trabectedin can
be administered safely to Japanese patients with STS. Thus,
the present study suggested that we warn toxic expression and
consider starting trabectedin treatment at 1.2 mg/m2 for Asian
patients.
Plasma trabectedin concentrations promptly decreased
after the completion of infusion, and the drug was
gradually eliminated. The cause of the abnormally high
drug concentration in a patient at dose level 2 is un-
clear, but the data were included in analysis. Owing to
this high plasma concentration of trabectedin, the coef-
ficients of variation for Cmax, AUC0-t, and AUCinf were
around 50 %, which indicated wide variability at dose
level 2. At dose level 3, high plasma trabectedin con-
centrations persisted after the completion of infusion in
two patients who had DLTs and severe elevations of
AST and ALT. Mean AUC0-t and AUCinf were slightly higher
than the respective values at the other dose levels, although
Cmax was similar. The fact that two patients had severe AEs at
dose level 3 may indicate a relation between pharmacokinetics
and toxicity.
CL and Vdss in our study were lower than the reported
values (CL: 51.44 L/h and Vdss: 4981 L) in a previous phase
II study in Caucasian patients with STS (PharmaMar SA,
2006). We compared our data with the reported PopPK model
data in Caucasian patients [19] using visual predictive checks
(VPC). Plasma concentrations in Japanese patients were
slightly higher than that of the population mean estimated by
the PopPKmodel for each dose level, and at higher dose level,
Fig. 1 Individual plasma concentration time profiles of trabectedin for a
dose level 1, b dose level 2 and c dose level 3
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several plasma concentrations were higher than the upper
range of VPC (Fig. 3a–c). Plasma concentrations at dose level
2 in our study seemed to correspond to plasma concentrations
at 1.5 mg/m2 trabectedin in Caucasian patients (Fig. 3d).
Because the clearance of trabectedin correlated with clearance
of midazolam, it is apparent that the clearance of trabectedin
depends on the hepatic clearance by CYP3A4 which is a main
metabolism enzyme for trabectedin [23]. It is reported that
there is not ethnic difference over individual difference in
pharmacokinetics of midazolam [24]. Currently, the reason
of the difference between Japanese andWestern patients in the
clearance of trabectedin is unclear.
As for the efficacy of trabectedin, the overall response rate
of 20 % was higher than the response rate obtained in a
retrospective analysis of phase II studies of trabectedin in
patients with advanced STS (7 % among 620 patients) [25].
The PFR of 60 % at 3 months also supported further investi-
gation of this agent for STS [26]. Encouraging disease control
by trabectedin was expected especially in TRS as reported
previously [27].
Table 3 Pharmacokinetic parameters of trabectedin
Level 1 (N=3) Level 2 (N=9) Level 3 (N=3)
Mean SD CV (%) Mean SD CV (%) Mean SD CV (%) n
tmax (h) 16.5 13.0 78.9 17.2 11.8 68.7 16.6 13.1 78.7 3
Cmax (pg/mL) 1570 997 63.3 2070 2950 142.0 1990 652 32.8 3
λz (1/h) 0.0037 0.0016 42.5 0.0060 0.0015 25.3 0.0056 NC NC 2
t1/2 (h) 221 126 57.2 124 35 28.5 174 NC NC 2
AUC0–48 (ng·h/mL) 33.3 15.8 47.5 35.3 18.5 52.4 53.5 14.9 27.8 3
AUC0-t (ng·h/mL) 46.9 17.3 36.8 53.9 25.3 46.8 96.3 29.0 30.1 3
AUCinf (ng·h/mL) 77.7 31.8 40.9 74.9 42.7 56.9 132 NC NC 2
CL (L/h/m2) 13.3 6.4 47.9 18.7 5.8 31.0 11.6 NC NC 2
Vdss (L/m
2) 2470 1210 48.8 2030 716 35.4 2110 NC NC 2
Vz (L/m
2) 3710 1170 31.6 3160 989 31.3 2710 NC NC 2
CL (L/h) 21.0 11.7 55.6 31.4 9.5 30.1 21.1 NC NC 2
Vdss (L) 3790 1810 47.6 3380 1050 31.0 3800 NC NC 2
Vz (L) 5730 1830 32.0 5290 1420 26.8 4900 NC NC 2
SD standard deviation, CV coefficients of variation
Fig. 2 MRI findings of a 21-year-old female patient with a recurrent retroperitoneal myxoid liposarcoma: a baseline, and after b 7 cycles (day 232), c
13 cycles (day 421) and d 19 cycles (day 672) of trabectedin at dose level 2 (1.2 mg/m2)
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In conclusion, recommended dose of trabectedin for phase
II clinical trials was 1.2 mg/m2 in Japanese patients with
advanced STS refractory to anthracyclines. A randomized
phase II study comparing 1.2 mg/m2 trabectedin with best
supportive care is ongoing in Japanese patients with TRS.
Further pharmacokinetic evaluations of trabectedin are sched-
uled to be performed in this phase II study to examine the
reasons for the difference in the recommended dose between
Japanese and Western patients.
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